MAREČKOVÁ, Andrea, Jitka MALČÍKOVÁ, Nikola TOM, Karol PÁL, Lenka RADOVÁ, David ŠÁLEK, Andrea JANÍKOVÁ, Mojmír MOULIS, Jana ŠMARDOVÁ, Leoš KŘEN, Jiří MAYER a Martin TRBUŠEK. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients. LEUKEMIA & LYMPHOMA. LONDON: INFORMA HEALTHCARE, 2019, roč. 60, č. 6, s. 1420-1428. ISSN 1042-8194. Dostupné z: https://dx.doi.org/10.1080/10428194.2018.1542144. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1545496, author = {Marečková, Andrea and Malčíková, Jitka and Tom, Nikola and Pál, Karol and Radová, Lenka and Šálek, David and Janíková, Andrea and Moulis, Mojmír and Šmardová, Jana and Křen, Leoš and Mayer, Jiří and Trbušek, Martin}, article_location = {LONDON}, article_number = {6}, doi = {http://dx.doi.org/10.1080/10428194.2018.1542144}, keywords = {Mantle cell lymphoma; ATM; TP53; p21; SOX11; survival}, language = {eng}, issn = {1042-8194}, journal = {LEUKEMIA & LYMPHOMA}, title = {ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients}, url = {http://dx.doi.org/10.1080/10428194.2018.1542144}, volume = {60}, year = {2019} }
TY - JOUR ID - 1545496 AU - Marečková, Andrea - Malčíková, Jitka - Tom, Nikola - Pál, Karol - Radová, Lenka - Šálek, David - Janíková, Andrea - Moulis, Mojmír - Šmardová, Jana - Křen, Leoš - Mayer, Jiří - Trbušek, Martin PY - 2019 TI - ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients JF - LEUKEMIA & LYMPHOMA VL - 60 IS - 6 SP - 1420-1428 EP - 1420-1428 PB - INFORMA HEALTHCARE SN - 10428194 KW - Mantle cell lymphoma KW - ATM KW - TP53 KW - p21 KW - SOX11 KW - survival UR - http://dx.doi.org/10.1080/10428194.2018.1542144 L2 - http://dx.doi.org/10.1080/10428194.2018.1542144 N2 - Mantle cell lymphoma (MCL) is characterized by the hallmark t(11;14)(q13;q32) translocation, leading to cyclin D1 over-expression. Additionally, disrupting the DNA damage response pathway through ATM or TP53 defects plays an important role in MCL pathogenesis. Using deep next-generation sequencing we analyzed the mutual composition of ATM and TP53 mutations in 72 MCL patients, and assessed their impact on progression-free survival (PFS) and overall survival (OS). Mutated ATM and TP53 alleles were found in 51% (37/72) and 22% (16/72) of the cases examined, respectively, with only three patients harboring mutations in both genes. Only a mutated TP53 gene was associated with the significantly reduced PFS and OS and the same output was observed when ATM and TP53 defective groups included also sole deletions 11q and 17p, respectively. Determining the exact ATM/p53 pathway dysfunction may influence the selection of MCL patients for innovative therapies based on the targeted inhibition of selected proteins. ER -
MAREČKOVÁ, Andrea, Jitka MALČÍKOVÁ, Nikola TOM, Karol PÁL, Lenka RADOVÁ, David ŠÁLEK, Andrea JANÍKOVÁ, Mojmír MOULIS, Jana ŠMARDOVÁ, Leoš KŘEN, Jiří MAYER a Martin TRBUŠEK. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients. \textit{LEUKEMIA \&{}amp; LYMPHOMA}. LONDON: INFORMA HEALTHCARE, 2019, roč.~60, č.~6, s.~1420-1428. ISSN~1042-8194. Dostupné z: https://dx.doi.org/10.1080/10428194.2018.1542144.
|